Register free for our breaking news email alerts with analysis and cutting edge commentary from our award winning team. Registration only takes a minute.

AXA Framlington Biotech R Acc

Ranked 6 out of 10 in - Biotechnology over 12 months
All calculations are in GBP unless stated

Managed by

Linden Thomson

London based, Linden Thomson is part of the AXA team. She has been managing the AXA Framlington Biotech fund since July 2012. Thomson studied at University of Edinburgh where she gained the BSc Medical Microbiology. She has earned the Chartered Financial Analyst (CFA) charter.

Objective

The Fund invests in shares of listed companies, principally in the biotechnology, genomic and medical research industry, which the Manager believes will provide above-average returns. The Fund invests in companies of any size which can be based anywhere in the world, albeit the Fund tends to be biased towards the US as this is where the majority of biotechnology companies are based. The Manager selects shares based upon analysis of a companys financial status, quality of its management, expected profitability and prospects for growth.

Showing fund performance in United Kingdom View performance globally

Performance

Biotechnology over : 31/03/2018 - 31/03/2019

Total Return

Quarterly Performance

to 31/03/2019 Annual Q1 Q2 Q3 Q4
2019 15.9%
2018 -7.3% -1.8% 9.1% 10.5% -21.7%
2017 8.6% 7.2% 1.6% 4.0% -4.1%
2016 -5.9% -21.9% 4.2% 17.7% -1.7%
2015 11.2% 19.6% -2.0% -17.4% 14.9%
2014 45.3% 0.7% 9.2% 12.8% 17.1%
2013 63.7% 24.2% 9.4% 14.2% 5.5%
2012 24.3% 15.3% 4.9% 8.4% -5.2%
2011 7.6% 0.6% 6.1% -9.6% 11.6%
2010 9.8% 13.4% -16.2% 3.7% 11.5%
2009 3.7% 0.4% -2.8% 10.7% -4.0%
2008 15.5% -9.2% 2.3% 12.9% 10.1%
2007 -3.9% -0.7% -0.5% -2.2% -0.5%
2006 0.5% 13.3% -19.6% 0.6% 9.7%
2005 10.1% -15.2% 14.2% 13.4% 0.3%
2004 1.7% 6.3% -7.9% -2.2% 6.2%
2003 43.9% -3.9% 30.9% 13.8% 0.5%
2002 -53.1% -19.7% -35.8% -17.2% 9.9%

Month by Month Performance

Returns Vs Risk

Asset Allocation

Breakdown

28/02/2019

Top 10 Holdings

Stock Size
Biogen Inc ORD 9.05%
Alexion Pharmaceuticals Inc ORD 7.60%
Gilead Sciences Inc ORD 6.57%
Celgene Corp ORD 5.77%
Regeneron Pharmaceuticals Inc ORD 4.60%
Amgen Inc ORD 4.36%
Biomarin Pharmaceutical Inc ORD 3.17%
GBP Cash 3.13%
Ionis Pharmaceuticals Inc ORD 3.10%
Takeda Pharmaceutical Co Ltd ORD 2.94%
28/02/2019

Registered For Sale In

  1. United Kingdom

Fund Info

  • Launch date26/11/2001
  • Share Class size466Mn
  • Base currencyGBP
  • ISIN GB0031007254

Purchase Info

  • Min. initial investment1,000
  • Min. regular additional investment50

Charges

  • Annual management1.75%
  • Initial investment0.00%

Related News

Chinese biotech - growth, innovation and urgency

The need for self-sufficiency is driving drug fast-tracking.

Performance is for the period shown (month end to month end, bid/bid, gross income reinvested, calculated in the currency and currencies indicated).